Calidi Biotherapeutics (NYSE American: CLDI) is advancing toward a Q4 2026 IND filing for CLD-401, its RedTail platform lead candidate designed to systemically deliver IL-15 superagonist directly to tumor sites in patients with metastatic disease. With preclinical data showcasing tumor-specific replication and immune clearance avoidance, Calidi plans to expand into BiTE/T-cell amplifier co-delivery, and even non-oncology indications—positioning RedTail as a versatile, next-gen genetic medicine platform across therapeutic areas.

OBOOK Holdings (Nasdaq: OWLS) and ARTA Global Markets have teamed up to deliver a high-speed, compliant digital asset on/off ramp and cross-currency payment solution through OwlPay. Leveraging over 40 U.S. and Japan licenses and AGML’s SFC-regulated infrastructure, the platform supports same-day settlements across 30+ currencies—streamlining digital-to-fiat conversion for institutional clients across Asia, the Americas, and G7 economies.

Greenwich LifeSciences (Nasdaq: GLSI) has more than doubled its cash position to ~$12.5M in early 2026 through its ATM program—potentially covering all of 2026 burn, thanks to lean operations and a modest $9.5M burn rate in 2025. With FLAMINGO-01’s non-HLA-A*02 arm fully enrolled and showing an ~80% reduction in breast cancer recurrence post-primary immunization, the company is well-positioned to fund this Phase III trial through key milestones without large near-term financings.

Enlivex Therapeutics (Nasdaq: ENLV) announced the listing of its primary digital treasury asset, the RAIN token, on WhiteBIT—Europe’s largest crypto exchange by traffic. The move expands global access and enhances liquidity for RAIN, supporting Enlivex’s pioneering digital asset treasury strategy alongside its clinical focus on Allocetra™ for osteoarthritis, a condition affecting over 300 million people worldwide.